COMMUNIQUÉS West-GlobeNewswire

-
EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation
17/07/2025 -
EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation
17/07/2025 -
MYOS PET and Leading Veterinarian Urge Action as Weather Extremes Impact Senior Pet Muscle Health
17/07/2025 -
Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
17/07/2025 -
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
17/07/2025 -
Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call
17/07/2025 -
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
17/07/2025 -
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
17/07/2025 -
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
17/07/2025 -
Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink
17/07/2025 -
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
17/07/2025 -
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
17/07/2025 -
Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache
17/07/2025 -
Repligen to Report Second Quarter 2025 Financial Results
17/07/2025 -
Peptides For Muscle Growth: How Oral Legal Peptides by Crazy Bulk Set New Benchmark For Bodybuilding Supplements and Muscle Building Results
17/07/2025 -
KFSHRC Performs World’s First Robotic-Assisted BiVAD Implantation
17/07/2025 -
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
17/07/2025 -
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
17/07/2025 -
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
17/07/2025
Pages